Abstract
Heart rate is a major determinant of cardiac output and myocardial oxygen utilization and is increasingly being nominated as a modifiable risk factor for cardiovascular disease. Despite this evidence, screening strategies for preventing cardiovascular diseases do not include routine assessment of resting heart rate. Reasonably, heart rate reduction has been suggested as a useful approach against angina pectoris in subjects with acute or chronic coronary syndromes. Accordingly, reduction of heart rate in patients with stable angina could be an additional goal of therapy. Important data have shown retrospectively the beneficial effect of heart rate-lowering drugs, such as betaadrenoceptor antagonists, non-dihydropyridine calcium channel antagonists, as well as other agents, on several parameters in patients with coronary artery disease and stable angina. However, additional data are now being sought to assess the impact of this approach on clinical practice.
Keywords: Stable angina, heart rate, therapeutic target, beta-blockers, ivabradine, ranolazine, cardiac output, myocardial oxygen, cardiovascular diseases, non-dihydropyridine calcium channel
Current Pharmaceutical Design
Title:Heart Rate as a Therapeutic Target in Angina Pectoris
Volume: 19 Issue: 9
Author(s): Emmanuel Androulakis, Dimitris Tousoulis, Nikolaos Papageorgiou, Anna Kontogeorgou, Alexandros Briasoulis, Marietta Charakida, Gerasimos Siasos, Evangelos Oikonomou, Katerina Siama, George Latsios and Christodoulos Stefanadis
Affiliation:
Keywords: Stable angina, heart rate, therapeutic target, beta-blockers, ivabradine, ranolazine, cardiac output, myocardial oxygen, cardiovascular diseases, non-dihydropyridine calcium channel
Abstract: Heart rate is a major determinant of cardiac output and myocardial oxygen utilization and is increasingly being nominated as a modifiable risk factor for cardiovascular disease. Despite this evidence, screening strategies for preventing cardiovascular diseases do not include routine assessment of resting heart rate. Reasonably, heart rate reduction has been suggested as a useful approach against angina pectoris in subjects with acute or chronic coronary syndromes. Accordingly, reduction of heart rate in patients with stable angina could be an additional goal of therapy. Important data have shown retrospectively the beneficial effect of heart rate-lowering drugs, such as betaadrenoceptor antagonists, non-dihydropyridine calcium channel antagonists, as well as other agents, on several parameters in patients with coronary artery disease and stable angina. However, additional data are now being sought to assess the impact of this approach on clinical practice.
Export Options
About this article
Cite this article as:
Androulakis Emmanuel, Tousoulis Dimitris, Papageorgiou Nikolaos, Kontogeorgou Anna, Briasoulis Alexandros, Charakida Marietta, Siasos Gerasimos, Oikonomou Evangelos, Siama Katerina, Latsios George and Stefanadis Christodoulos, Heart Rate as a Therapeutic Target in Angina Pectoris, Current Pharmaceutical Design 2013; 19 (9) . https://dx.doi.org/10.2174/1381612811319090003
DOI https://dx.doi.org/10.2174/1381612811319090003 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Substance-Related Disorders and Somatic Symptoms: How Should Clinicians Understand the Associations?
Current Drug Abuse Reviews Supplementation, Optimal Status, and Analytical Determination of Vitamin D: Where are we Standing in 2012?
Anti-Cancer Agents in Medicinal Chemistry Screening for Silent Coronary Artery Disease in Diabetics- or Not?
Current Diabetes Reviews Pharmacokinetic-Pharmacodynamic Modeling of Antihypertensive Drugs: From Basic Research to Clinical Practice
Current Hypertension Reviews Itraconazole Induced Congestive Heart Failure, A Case Study
Current Drug Safety Malignancy and Radiation-Induced Cardiotoxicity
Cardiovascular & Hematological Disorders-Drug Targets Cardiovascular Effects of Losartan and Its Relevant Clinical Application
Current Medicinal Chemistry The Relationship between Inflammatory and Oxidative Stress Biomarkers, Atherosclerosis and Rheumatic Diseases
Current Pharmaceutical Design Heterocycles in the Treatment of Neglected Tropical Diseases
Current Medicinal Chemistry Simulating the Interactions of Toxins with K+ Channels
Current Pharmaceutical Design CD45 Regulated Signaling Pathways
Current Topics in Medicinal Chemistry Chronic Inflammatory Disorders and Accelerated Atherosclerosis: Chronic Kidney Disease
Current Pharmaceutical Design Statins and epilepsy: preclinical studies, clinical trials and statin-anticonvulsant drug interactions
Current Drug Targets Inflammatory Syndrome in Chronic Kidney Disease: Pathogenesis and Influence on Outcomes
Inflammation & Allergy - Drug Targets (Discontinued) Diabetes Trends in Hospitalized HIV-Infected Persons in the United States, 1994-2004
Current HIV Research Nutraceuticals - An Emerging Era in the Treatment and Prevention of Cardiovascular Diseases
Current Pharmaceutical Biotechnology New Insights into Vitamin D and Autophagy in Inflammatory Bowel Diseases
Current Medicinal Chemistry Mild Systemic Inflammation has a Neuroprotective Effect After Stroke in Rats
Current Neurovascular Research The Role of FKBP5 in Mood Disorders: Action of FKBP5 on Steroid Hormone Receptors Leads to Questions About its Evolutionary Importance
CNS & Neurological Disorders - Drug Targets Is there a Role for Cortisol in the Accumulation of Lipids in the Intima a Crucial Step of Atherogenesis?
Current Vascular Pharmacology